Paracrine role for TGF-β-induced CTGF and VEGF in mesangial matrix expansion in progressive glomerular disease

Histology and Histopathology

Volumn 27, Issue 9, 2012, Pages 1131-1141

  Lee, Hyun Soon ^a  

^a Seoul National University   (South Korea)

Author keywords

5 1 integrin; CCN2; Chronic glomerular disease; Fibronectin; Mesangial matrix; Podocyte TGF ; VEGF VEGF receptor system

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; CTGF PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN A;

ANIMAL; FOCAL GLOMERULOSCLEROSIS; HUMAN; MESANGIUM; METABOLISM; PARACRINE SIGNALING; PATHOLOGY; PHYSIOLOGY; PODOCYTE; REVIEW;

ANIMALS; CONNECTIVE TISSUE GROWTH FACTOR; GLOMERULAR MESANGIUM; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; PARACRINE COMMUNICATION; PODOCYTES; TRANSFORMING GROWTH FACTOR BETA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84866107053     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (113)

1. Abbate M., Zoja C., Morigi M., Rottoli D., Angioletti S., Tomasoni S., Zanchi C., Longaretti L., Donadelli R. and Remuzzi G. (2002). Transforming growth factor-β1 is up-regulated by podocytes in response to excess intraglomerular passage of proteins: a central pathway in progressive glomerulosclerosis. Am. J. Pathol. 161, 2179-2193.
2. Amemiya T., Sasamura H., Mifune M., Kitamura Y., Hirahashi J., Hayashi M. and Saruta T. (1999). Vascular endothelial growth factor activates MAP kinase and enhances collagen synthesis in human mesangial cells. Kidney Int. 56, 2055-2063.
3. Baelde H.J., Eikmans M., Lappin D.W.P., Doran P.P., Hohenadel D., Brinkkoetter P.-T., van der Woude F.J., Waldherr R., Rabelink T.J., de Heer E. and Bruijn J.A. (2007). Reduction of VEGF-A and CTGF expression in diabetic nephropathy is associated with podocyte loss. Kidney Int. 71, 637-645.
4. Bailey E., Bottomley M.J., Westwell S., Pringle J.H., Furness P.N., Feehally J., Brenchley P.E.C. and Harper S.J. (1999). Vascular endothelial growth factor mRNA expression in minimal change, membranous, and diabetic nephropathy demonstrated by nonisotopic in situ hybridization. J. Clin. Pathol. 52, 735-738.
5. Blom I.E., van Dijk A.J., Wieten L., Duran K., Ito Y., Kleij L, deNichilo M., Rabelink T.J., Weening J.J., Aten J. and Goldschmeding R. (2001). In vitro evidence for differential involvement of CTGF, TGFβ, and PDGF-BB in mesangial response to injury. Nephrol. Dial. Transplant. 16, 1139-1148.
6. Bortoloso E., Del Prete D., Dalla Vestra M., Gambaro G., Saller A., Antonucci F., Baggio B., Anglani F. and Fioretto P. (2004). Quantitative and qualitative changes in vascular endothelial growth factor gene expression in glomeruli of patients with type 2 diabetes. Eur. J. Endocrinol. 150, 799-807.
7. Chen S., Iglesias-de la Cruz M.C., Jim B., Hong S.W., Isono M. and Ziyadeh F.N. (2003). Reversibility of established diabetic glomerulopathy by anti-TGF-β antibodies in db/db mice. Biochem. Biophys. Res. Commun. 300, 16-22.
8. Chen S., Kasama Y., Lee J.S., Jim B., Marin M. and Ziyadeh F.N. (2004a). Podocyte-derived vascular endothelial growth factor mediates the stimulation of α3(IV) collagen production by transforming growth factor-β1 in mouse podocytes. Diabetes 53, 2939-2949.
9. Chen Y., Abraham D.J., Shi-Wen X., Pearson J.D., Black C.M., Lyons K.M. and Leask A. (2004b). CCN2 (connective tissue growth factor) promotes fibroblast adhesion to fibronectin. Mol. Biol. Cell 15, 5635-5646.
10. Chen S., Lee J.S., Iglesias-de la Cruz M.C., Wang A., Izquierdo- Lahuerta A., Gandhi N.K., Danesh F.R., Wolf G. and Ziyadeh F.N. (2005). Angiotensin II stimulates α3(IV) collagen production in mouse podocytes via TGF-β and VEGF signaling: implications for diabetic glomerulopathy. Nephrol. Dial. Transplant. 20, 1320-1328.
11. Chiang H.-Y., Korshunov V.A., Serour A., Shi F. and Sottile J. (2009). Fibronectin is an important regulator of flow-induced vascular remodeling. Arterioscler. Thromb. Vasc. Biol. 29, 1074-1079.
12. Cooper M.E., Vranes D., Youssef S., Stacker S.A., Cox A.J., Rizkalla B., Casley D.J., Bach L.A., Kelly D.J. and Gilbert R.E. (1999). Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 48, 2229-2239.
13. Crean J.K.G., Finlay D., Murphy M., Moss C., Godson C., Martin F. and Brady H.R. (2002). The role of p42/44 MAPK and protein kinase B in connective tissue growth factor induced extracellular matrix protein production, cell migration, and actin cytoskeletal rearrangement in human mesangial cells. J. Biol. Chem. 277, 44187-44194.
14. Cui T.-G., Foster R.R., Saleem M., Mathieson P.W., Gillatt D.A., Bates D.O. and Harper S.J. (2004). Differentiated human podocytes endogenously express an inhibitory isoform of vascular endothelial growth factor (VEGF165b) mRNA and protein. Am. J. Physiol. Renal Physiol. 286, F767-773.
15. Daniel C., Schaub K., Amann K., Lawler J. and Hugo C. (2007). Thrombospondin-1 is an endogenous activator of TGF-β in experimental diabetic nephropathy in vivo. Diabetes 56, 2982-2989.
16. De Vriese A.S., Tilton R.G., Elger M., Stephan C.C., Kriz W. and Lameire N.H. (2001). Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J. Am. Soc. Nephrol. 12, 993-1000.
17. Eremina V., Sood M., Haigh J., Nagy A., Lajoie G., Ferrara N., Gerber H.-P., Kikkawa Y., Miner J.H. and Quaggin S.E. (2003). Glomerularspecific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J. Clin. Invest. 111, 707-716.
18. Ferrara N., Gerber H.P. and LeCouter J. (2003). The biology of VEGF and its receptors. Nat. Med. 9, 669-676.
19. Flyvbjerg A., Dagnaes-Hansen F., De Vriese A.S., Schrijvers B.F., Tilton R.G. and Rasch R. (2002). Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes 51, 3090-3094.
20. Foster R.R. (2009). The importance of cellular VEGF bioactivity in the development of glomerular disease. Nephron Exp. Nephrol. 113, e8-e15.
21. Fuchshofer R., Ullmann S., Zeilbeck L.F., Baumann M., Junglas B. and Tamm E.R. (2011). Connective tissue growth factor modulates podocyte actin cytoskeleton and extracellular matrix synthesis and is induced in podocytes upon injury. Histochem. Cell Biol. 136, 301-319.
22. Geiger B., Bershadsky A., Pankov R. and Yamada K.M. (2001). Transmembrane extracellular matrix-cytoskeleton crosstalk. Nat. Rev. Mol. Cell Biol. 2, 793-805.
23. Gore-Hyer E., Shegogue D., Markiewicz M., Lo S., Hazaen-Martin D., Greene E.L., Grotendorst G. and Trojanowska M. (2002). TGF-β and CTGF have overlapping and distinct fibrogenic effects on human renal cells. Am. J. Physiol. Renal Physiol. 283, F707-F716.
24. Gortendorst G.R. (1997). Connective tissue growth factor: a mediator of TGF-β action on fibroblasts. Cytokine Growth Factor Rev. 8, 171-179.
25. Gregory M.C., Terreros D.A., Barker D.F., Fain P.N., Denison J.C. and Atkin C.L. (1996). Alport syndrome-clinical phenotypes, incidence, and pathology. Contrib. Nephrol. 117, 1-28.
26. Guan F., Villegas G., Teichman J., Mundel P. and Tufro A. (2006). Autocrine VEGF-A system in podocytes regulates podocin and its interaction with CD2AP. Am. J. Physiol. Renal Physiol. 291, F422-F428.
27. Guha M., Xu Z.G., Tung D., Lanting L. and Natarajan R. (2007). Specific down-regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes. FASEB J. 21, 3355-3368.
28. Haraldsson B., Barisoni L. and Quaggin S.E. (2008a). VEGF inhibition and renal thrombotic microangiopathy. N. Engl. J. Med. 359, 206-207.
29. Haraldsson B., Nyström J. and Deen W.M. (2008b). Properties of the glomerular barrier and mechanisms of proteinuria. Physiol. Rev. 88, 451-487.
30. Hilberg F., Roth G.J., Krssak M., Kautschitsch S., Sommergruber W., Tontsch-Grunt U., Garin-Chesa P., Bader G., Zoephel A., Quant J., Heckel A. and Rettig W.J. (2008). BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 68, 4774-4782.
31. Holmes A., Abraham D.J., Sa S., Shiwen X., Black C.M. and Leask A. (2001). CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling. J. Biol. Chem. 276, 10594-10601.
32. Honkanen E., von Willebrand E., Koskinen P., Teppo A.-M., Törnroth T., Ruutu M. and Grönhagen-Riska C. (2003). Decreased expression of vascular endothelial growth factor in idiopathic membranous glomerulonephritis: relationships to clinical course. Am. J. Kidney Dis. 42, 1139-1148.
33. Horita Y., Miyazaki M., Koji T., Kobayashi N., Shibuya M., Razzaque M.S., Cheng M., Ozono Y., Kohno S. and Taguchi T. (1998). Expression of vascular endothelial growth factor and its receptors in rats with protein-overload nephrosis. Nephrol. Dial. Transplant. 13, 2519-2528.
34. Iglesias-de la Cruz M.C., Ziyadeh F.N., Isono M., Kouahou M., Han D.C., Kalluri R., Mundel P. and Chen S. (2002). Effects of high glucose and TGF-β1 on the expression of collagen IV and vascular endothelial growth factor in mouse podocytes. Kidney Int. 62, 901-913.
35. Iijima K., Yoshikawa N., Connolly D.T. and Nakamura H. (1993). Human mesangial cells and peripheral blood mononuclear cells produce vascular permeability factor. Kidney Int. 44, 959-966.
36. Inoki I., Shiomi T., Hashimoto G., Enomoto H., Nakamura H., Makino K.-i., Ikeda E., Takata S., Kobayashi K.-I. and Okada Y. (2002). Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. FASEB J. 16, 219-221.
37. Iruela-Arispe L., Gordon K., Hugo C., Duijvestijn A.M., Claffey K.P., Reilly M., Couser W.G., Alpers C.E. and Johnson R.J. (1995). Participation of glomerular endothelial cells in the capillary repair of glomerulonephritis. Am. J. Pathol. 147, 1715-1727.
38. Ito Y., Aten J., Bende R.J., Oemar B.S., Rabelink T.J., Weening J.J. and Goldschmeding R. (1998). Expression of connective tissue growth factor in human renal fibrosis. Kidney Int. 53, 853-861.
39. Ito Y., Goldschmeding R., Bende R.J., Claessen N., Chand M.A., Kleij L., Rabelink T.J., Weening J.J. and Aten J. (2001). Kinectics of connective tissue growth factor expression during experimental proliferative glomerulonephritis. J. Am. Soc. Nephrol. 12, 472-484.
40. Ito Y., Goldschmeding R., Kasuga H., Claessen N., Nakayama M., Yuzawa Y., Sawai A., Matsuo S., Weening J.J. and Aten J. (2010). Expression patterns of connective tissue growth factor and of TGF-β isoforms during glomerular injury recapitulate glomerulogenesis. Am. J. Physiol. Renal Physiol. 299, F545-F558.
41. Kantarci A., Black S.A., Xydas C.E., Murawel P., Uchida Y., Yucekal-Tuncer B., Atilla G., Emingil G., Uzel M.I., Lee A., Firatli E., Sheff M., Hasturk H., Van Dyke T.E. and Trackman P.C. (2006). Epithelial and connective tissue cell CTGF/CCN2 expression in gingival fibrosis. J. Pathol. 210, 59-66.
42. Kendall R.L. and Thomas K.A. (1993). Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc. Natl. Acad. Sci. USA 90, 10705-10709.
43. Kim K.H., Kim Y., Gubler M.C., Steffes M.W., Lane P.H., Kashtan C.E., Crosson J.T. and Mauer S.M. (1995). Structural-functional relationships in Alport syndrome. J. Am. Soc. Nephrol. 5, 1659-1668.
44. Kim T.S., Kim J.Y., Hong H.K. and Lee H.S. (1999). mRNA expression of glomerular basement membrane proteins and TGF-β1 in human membranous nephropathy. J. Pathol. 189, 425-430.
45. Kim H.W., Moon K.C., Park S.Y., Hong H.K. and Lee H.S. (2002). Differential expression of platelet-derived growth factor and transforming growth factor-β in relation to progression of IgA nephropathy. Nephrology 7, S131-S139.
46. Kim J.H., Kim B.K., Moon K.C., Hong H.K. and Lee H.S. (2003). Activation of the TGF-β/Smad signaling pathway in focal segmental glomerulosclerosis. Kidney Int. 64, 1715-1721.
47. Kim H.W., Kim B.C., Song C.Y., Kim J.H., Hong H.K. and Lee H.S. (2004). Heterozygous mice for TGF-βIIR gene are resistant to the progression of streptozotocin-induced diabetic nephropathy. Kidney Int. 66, 1859-1865.
48. Koli K., Saharinen J., Hyytiäinen M., Penttinen C. and Keski-Oja J. (2001). Latency, activation, and binding proteins of TGF-β. Microsc. Res. Tech. 52, 354-362.
49. Koli K., Myllärniemi M., Keski-Oja J. and Kinnula V.L. (2008). Transforming growth factor-β activation in the lung: focus on fibrosis and reactive oxygen species. Antioxid. Redox. Signal 10, 333-342.
50. Kosugi T., Nakayama T., Li Q., Chiodo V.A., Zhang L., Campbell-Thompson M., Grant M., Crocker B.P. and Nakagawa T. (2010). Soluble Flt-1 gene therapy ameliorates albuminuria but accelerates tubulointerstitial injury in diabetic mice. Am. J. Physiol. Renal Physiol. 298, F609-F616.
51. Ku C.-H., White K.E., Dei Cas A., Hayward A., Webster Z., Bilous R., Marshall S., Viberti G. and Gnudi L. (2008). Inducible overexpression of sFlt-1 in podocytes ameliorates glomerulopathy in diabetic mice. Diabetes 57, 2824-2833.
52. Kuhara T., Kagami S. and Kuroda Y. (1997). Expression of β1-integrins on activated mesangial cells in human glomerulonephritis. J. Am. Soc. Nephrol. 8, 1679-1687.
53. Leask A., Sa S., Holmes A., Shiwen X., Black C.M. and Abraham D.J. (2001). The control of ccn2 (ctgf) gene expression in normal and scleroderma fibroblasts. Mol. Pathol. 54, 180-183.
54. Leask A., Holmes A., Black C.M. and Abraham D.J. (2003). Connective tissue growth factor gene regulation. Requirements for its induction by transforming growth factor-beta 2 in fibroblasts. J. Biol. Chem. 278, 13008-13015.
55. Lee H.S. (2011a). Pathogenic role of TGF-β in the progression of podocyte diseases. Histol. Histopathol. 26, 107-116.
56. Lee H.S. (2011b). Role of TGF-β in mesangial matrix accumulation in chronic progressive glomerular disease. In: An Update on Glomerulopathies - Etiology and Pathogenesis. Chapter 7. Prabhakar S. (ed). InTech. Rijeka, Croatia. pp 123-140.
57. Lee H.S. (2012). Mechanisms and consequences of TGF-β overexpression by podocytes in progressive podocyte disease. Cell Tissue Res. 347, 129-140.
58. Lee H.S. and Koh H.I. (1993). Nature of progressive glomerulosclerosis in human membranous nephropathy. Clin. Nephrol. 39, 7-16.
59. Lee H.S. and Lim S.D. (1995). The significance of glomerular hypertrophy in focal segmental glomerulosclerosis. Clin. Nephrol. 44, 349-355.
60. Lee H.S. and Song C.Y. (2009a). Oxidized low-density lipoprotein and oxidative stress in the development of glomerulosclerosis. Am. J. Nephrol. 29, 62-70.
61. Lee H.S. and Song C.Y. (2009b). Differential role of mesangial cells and podocytes in TGF-β-induced mesangial matrix synthesis in chronic glomerular disease. Histol. Histopathol. 24, 901-908.
62. Li Z., Zhang Y., Ying Ma J., Kapoun A.M., Shao Q., Kerr I., Lam A., O'Young G., Sannajust F., Stathis P., Schreiner G., Karumanchi S.A., Protter A.A. and Pollitt N.S. (2007). Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension 50, 686-692.
63. Lin S.L., Chen R.H., Chen Y.M., Chiang W.C., Lai C.F., Wu K.D. and Tsai T.J. (2005). Pentoxifyline attenuates tubulointerstitial fibrosis by blocking Smad3/4-activated transcription and profibrogenic effects of connective tissue growth factor. J. Am. Soc. Nephrol. 16, 2702-2713.
64. Liu N., Makino T., Nogaki F., Kusano H., Suyama K., Muso E., Honda G., Kita T. and Ono T. (2004). Coagulation in the mesangial area promotes ECM accumulation through factor V expression in MsPGN in rats. Am. J. Physiol. Renal Physiol. 287, F612-F620.
65. Liu E., Morimoto M., Kitajima S., Koike T., Yu Y., Shiiki H., Nagata M., Watanabe T. and Fan J. (2007). Increased expression of vascular endothelial growth factor in kidney leads to progressive impairment of glomerular functions. J. Am. Soc. Nephrol. 18, 2094-2104.
66. Luo G.H., Lu Y.P., Song J., Yang L., Shi Y.J. and Li Y.P. (2008). Inhibition of connective tissue growth factor by small interfering RNA prevents renal fibrosis in rats undergoing chronic allograft nephropathy. Transplant. Proc. 40, 2365-2369.
67. Mao Y. and Schwarzbauer J.E. (2005). Stimulatory effects of a threedimensional microenvironment on cell-mediated fibronectin fibrillogenesis. J. Cell Sci. 118, 4427-4436.
68. Mason R.M. (2009). Connective tissue growth factor (CCN2), a pathogenic factor in diabetic nephropathy. What does it do? How does it do it? J. Cell Commun. Signal 3, 95-104.
69. Mason R.M. and Wahab N.A. (2003). Extracellular matrix metabolism in diabetic nephropathy. J. Am. Soc. Nephrol. 14, 1358-1373.
70. McKeown-Longo P.J. and Mosher D.F. (1985). Interaction of the 70,000-mol-wt amino-terminal fragment of fibronectin with the matrix-assembly receptor of fibroblasts. J. Cell Biol. 100, 364-374.
71. McLennan S.V., Wang X.Y., Moreno V., Yue D.K. and Twigg S.M. (2004). Connective tissue growth factor mediates high glucose effects on matrix degradation through tissue inhibitor of matrix metalloproteinase type 1: implications for diabetic nephropathy. Endocrinology 145, 5646-5655.
72. Noguchi K., Yoshikawa N., Ito-Kariya S., Inoue Y., Hayashi Y., Ito H., Nakamura H. and Iijima K. (1998). Activated mesangial cells produce vascular permeability factor in early-stage mesangial proliferative glomerulonephritis. J. Am. Soc. Nephrol. 9, 1815-1825.
73. Okada H., Kikuta T., Kobayashi T., Inoue T., Kanno Y., Takigawa M., Sugaya T., Kopp J.B. and Suzuki H. (2005). Connective tissue growth factor expressed in tubular epithelium plays a pivotal role in renal fibrogenesis. J. Am. Soc. Nephrol. 16, 133-143.
74. Oomura A., Nakamura T., Arakawa M., Ooshima A. and Isemura M. (1989). Alterations in the extracellular matrix components in human glomerular diseases. Virchows Arch. (A) 415, 151-159.
75. Otsuka G., Stempien-Otero A., Frutkin A.D. and Dichek D.A. (2007). Mechanisms of TGF-β1-induced intimal growth: plasminogen independent activities of plasminogen activator inhibitor-1 and heterogeneous origin of intimal cells. Circ. Res. 100, 1300-1307.
76. Patek C.E., Fleming S., Miles C.G., Bellamy C.O., Ladomery M., Spraggon L., Mullins J., Hastie N.D. and Hooper M.L. (2003). Murine Denys-Drash syndrome: evidence of podocyte de-differentiation and systemic mediation of glomerulosclerosis. Hum. Mol. Genet. 12, 2379-2394.
77. Richeldi L., Costabel U., Selman M., Kim D.S., Hansell D.M., Nicholson A.G., Brown K.K., Flaherty K.R., Noble P.W., Raghu G., Brun M., Gupta A., Juhel N., Klüglich M. and du Bois R.M. (2011). Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N. Engl. J. Med. 365, 1079-1087.
78. Riser B.L., Denichilo M., Cortes P., Baker C., Grondin J.M., Yee J. and Narins R.G. (2000). Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J. Am. Soc. Nephrol. 11, 25-38.
79. Roestenberg P., van Nieuwenhoven F.A., Joles J.A., Trischberger C., Martens P.P., Oliver N., Aten J., Höppener J.W. and Goldschmeding R. (2006). Temporal expression profile and distribution pattern indicate a role of connective tissue growth factor (CTGF/CCN-2) in diabetic nephropathy in mice. Am. J. Physiol. Renal Physiol. 290, F1344-F1354.
80. Sayers R., Kalluri R., Rodgers K.D., Shield C.F. III, Meehan D.T. and Cosgrove D. (1999). Role for transforming growth factor-β1 in Alport renal disease progression. Kidney Int. 56, 1662-1673.
81. Schroppel B., Huber S., Horster M., Schlondorff D. and Kretzler M. (1998). Analysis of mouse glomerular podocyte mRNA by single-cell reverse transcription-polymerase chain reaction. Kidney Int. 53, 119-124.
82. Schumacher V.A., Jeruschke S., Eitner F., Becker J.U., Pitschke G., Ince Y., Miner J.H., Leuschner I., Engers R., Everding A.S., Buila M. and Royer-Pokora B. (2007). Impaired glomerular maturation and lack of VEGF165b in Denys-Drash syndrome. J. Am. Soc. Nephrol. 18, 719-729.
83. Schwarzbauer J.E. and DeSimone D.W. (2011). Fibronectins, their fibrillogenesis, and in vivo functions. Cold Spring Harb. Perspect. Biol. 3, a005041.
84. Schwarzbauer J.E. and Sechler J.L. (1999). Fibronectin fibrillogenesis: a paradigm for extracellular matrix assembly. Curr. Opin. Cell. Biol. 11, 622-627.
85. Shulman K., Rosen S., Tognazzi K., Manseau E.J. and Brown L.F. (1996). Expression of vascular permeability factor (VPF/VEGF) is altered in many glomerular diseases. J. Am. Soc. Nephrol. 7, 661-666.
86. Sison K., Eremina V., Baelde H., Min W., Hirashima M., Fantus I.G. and Quaggin S.E. (2010). Glomerular structure and function require paracrine, not autocrine, VEGF-VEGFR-2 signaling. J. Am. Soc. Nephrol. 21, 1691-1701.
87. Sottile J. and Hocking D.C. (2002). Fibronectin polymerization regulates the composition and stability of extracellular matrix fibrils and cellmatrix adhesions. Mol. Biol. Cell 13, 3546-3559.
88. Sugimoto H., Hamano Y., Charytan D., Cosgrove D., Kieran M., Sudhakar A. and Kalluri R. (2003). Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J. Biol. Chem. 278, 12605-12608.
89. Sung S.H., Ziyadeh F.N., Wang A., Pyagay P.E., Kanwar Y.S. and Chen S. (2006). Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice. J. Am. Soc. Nephrol. 17, 3093-3104.
90. Suzama K., Naruse K., Suzama I., Takahara N., Ueki K., Aiello L.P. and King G.L. (2000). Vascular endothelial growth factor induces expression of connective tissue growth factor via KDR, Flt1, and phosphatidylinositol 3-kinase-akt-dependent pathways in retinal vascular cells. J. Biol. Chem. 275, 40725-40731.
91. Suzuki D., Toyoda M., Umezono T., Uehara G., Zhang S.-Y., Sakai T., Nishina M., Suga T., Endoh M., Yagame M. and Sakai H. (2003). Glomerular expression of connective tissue growth factor mRNA in various renal diseases. Nephrology 8, 92-97.
92. Taipale J., Koli K. and Keski-Oja J. (1992). Release of transforming growth factor-β1 from the pericellular matrix of cultured fibroblasts and fibrosarcoma cells by plasmin and thrombin. J. Biol. Chem. 267, 25378-25384.
93. Taneda S., Pippin J.W., Sage E.H., Hudkins K.L., Takeuchi Y., Couser W.G. and Alpers C.E. (2003). Amelioration of diabetic nephropathy in SPARC-null mice. J. Am. Soc. Nephrol. 14, 968-980.
94. Thomas S., Vanuystel J., Gruden G., Rodriguez V., Burt D., Gnudi L., Hartley B. and Viberti G. (2000). Vascular endothelial growth factor receptors in human mesangium in vitro and in glomerular disease. J. Am. Soc. Nephrol. 11, 1236-1243.
95. To W.S. and Midwood K.S. (2011). Plasma and cellular fibronectin: distinct and independent functions during tissue repair. Fibrogenesis Tissue Repair 4, 21.
96. Tsuchida K., Makita Z., Yamagishi S., Atsumi T., Miyoshi H., Obara S., Ishida M., Ishikawa S., Yasumura K. and Koike T. (1999). Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195. Diabetologia 42, 579-588.
97. Turk T., Leeuwis J.W., Gray J., Torti S.V., Lyons K.M., Nguyen T.Q. and Goldschmeding R. (2009). BMP signaling and podocyte markers are decreased in human diabetic nephropathy in association with CTGF overexpression. J. Histochem. Cytochem. 57, 623-631.
98. Van Vliet A., Baelde H.J., Vleming L.J., de Heer E. and Bruijn J.A. (2001). Distribution of fibronectin isoforms in human renal disease. J. Pathol. 193, 256-262.
99. Veron D., Reidy K.J., Bertuccio C., Teichman J., Villegas G., Jimenez J., Shen W., Kopp J.B., Thomas D.B. and Tufro A. (2010). Overexpression of VEGF-A in podocytes of adult mice causes glomerular disease. Kidney Int. 77, 989-999.
100. Wahab N.A. and Mason R.M. (2004). Connective tissue growth factor and renal diseases: some answers, more questions. Curr. Opin. Nephrol. Hypertens. 13, 53-58.
101. Wahab N.A., Yevdokimova N., Weston B.S., Roberts T., Li X.J., Brinkman H. and Mason R.M. (2001). Role of connective tissue growth factor in the pathogenesis of diabetic nephropathy. Biochem. J. 359, 77-87.
102. Wahab N.A., Schaefer L., Weston B.S., Yiannikouris O., Wright A., Babelova A., Schaefer R. and Mason R.M. (2005a). Glomerular expression of thrombospondin-1, transforming growth factor beta and connective tissue growth factor at different stages of diabetic nephropathy and their interdependent roles in mesangial response to diabetic stimuli. Diabetologia 48, 2650-2660.
103. Wahab N.A., Weston B.S. and Mason R.M. (2005b). Connective tissue growth factor CCN2 interacts with and activates the tyrosine kinase receptor Trka. J. Am. Soc. Nephrol. 16, 340-351.
104. Wang L., Kwak J.H., Kim S.I., He Y. and Choi M.E. (2004). Transforming growth factor-β1 stimulates vascular endothelial growth factor 164 via mitogen-activated protein kinase kinase 3- p38α and p38δ mitogen-activated protein kinase-dependent pathway in murine mesangial cells. J. Biol. Chem. 279, 33213-33219.
105. Wang A., Ziyadeh F.N., Lee E.Y., Pyagay P.E., Sung S.H., Sheardown S.A., Laping N.J. and Chen S. (2007). Interference with TGF-β signaling by Smad3-knockout in mice limits diabetic glomerulosclerosis without affecting albuminuria. Am. J. Physiol. Renal Physiol. 293, F1657-F1665.
106. Wendt T.M., Tanji N., Guo J., Kislinger T.R., Qu W., Lu Y., Bucciarelli L.G., Rong L.L., Moser B., Markowitz G.S., Stein G., Bierhaus A., Liliensiek B., Arnold B., Nawroth P.P., Stern D.M., D'Agati V.D. and Schmidt A.M. (2003). RAGE drives the develolpment of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am. J. Pathol. 162, 1123-1137.
107. Weston B.S., Wahab N.A. and Mason R.M. (2003). CTGF mediates TGF-β-induced fibronectin matrix deposition by upregulating active α5β1 integrin in human mesangial cells. J. Am. Soc. Nephrol. 14, 601-610.
108. Wolf G., Chen S. and Ziyadeh F.N. (2005). From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes 54, 1626-1634.
109. Yevdokimova N., Wahab N.A. and Mason R.M. (2001). Thrombospondin-1 is the key activatior of TGF-beta1 in human mesangial cells exposed to high glucose. J. Am. Soc. Nephrol. 12, 703-712.
110. Yokoi H., Mukoyama M., Sugawara A., Mori K., Nagae T., Makino H., Suganami T., Yahata K., Fujinaga Y., Tanaka I. and Nakao K. (2002). Role of connective tissue growth factor in fibronectin expression and tubulointerstitial fibrosis. Am. J. Physiol. Renal Physiol. 282, F933-F942.
111. Yokoi H., Mukoyama M., Nagae T., Mori K., Suganami T., Sawai K., Yoshioka T., Koshikawa M., Nishida T., Takigawa M., Sugawara A. and Nakao K. (2004). Reduction in connective tissue growth factor by antisense treatment ameliorates renal tubulointerstitial fibrosis. J. Am. Soc. Nephrol. 15, 1430-1440.
112. Yokoi H., Mukoyama M., Mori K., Kasahara M., Suganami T., Sawai K., Yoshioka T., Saito Y., Ogawa Y., Kuwabara T., Sugawara A. and Nakao K. (2008). Overexpression of connective tissue growth factor in podocytes worsens diabetic nephropathy in mice. Kidney Int. 73, 446-455.
113. Ziyadeh F.N., Hoffman B.B., Han D.C., Iglesias-dela Cruz M.C., Hong S.W., Isono M., Chen S., McGowan T.A. and Sharma K. (2000). Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-β antibody in db/db diabetic mice. Proc. Natl. Acad. Sci. USA 97, 8015-8020.